Peptide Comparison
DihexavsP21 (P021)
Angiotensin IV-derived oligopeptide that potentiates hepatocyte growth factor to drive synaptogenesis and cognitive enhancement with extraordinary potency
CNTF-derived neurotrophic tetrapeptide mimetic that promotes neurogenesis, enhances BDNF expression, and demonstrates disease-modifying potential in Alzheimer's models
At a Glance
Quick
comparison
Dose Range
Dihexa
8–20 mg
P21 (P021)
500–1000 mcg
Frequency
Dihexa
Once daily
P21 (P021)
Once daily
Administration
Dihexa
Oral (capsule/tablet)
P21 (P021)
Intranasal (spray)
Cycle Length
Dihexa
4-6 weeks
P21 (P021)
8-12 weeks
Onset Speed
Dihexa
Moderate (1-2 weeks)
P21 (P021)
Gradual (3-4 weeks)
Evidence Level
Dihexa
Preclinical only — animal and cell-culture studies; no human trials
P21 (P021)
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Cognitive
Healing & Recovery
Anti-Aging
Technical Data
Compound
specifications
Dihexa
Molecular Formula
C27H44N4O5
Molecular Weight
504.7 g/mol
Half-Life
~12 days (following IV administration in rats)
Bioavailability
Orally active and blood-brain barrier permeable — specific oral bioavailability percentage not published
CAS Number
1401708-83-5
P21 (P021)
Molecular Formula
C30H54N6O5
Molecular Weight
578.3 g/mol
Half-Life
>6 hours (for parent Peptide 6; P21 expected similar or improved due to adamantane modification)
Bioavailability
Orally bioavailable; BBB permeable (confirmed in preclinical studies)
CAS Number
Not assigned (research compound)
Protocols
Dosing
tiers
Dihexa
P21 (P021)
Applications
Best
suited for
Dihexa
Age-Related Cognitive Decline
Dihexa directly addresses the synaptic loss that underlies age-related cognitive decline by building new functional synaptic connections in the hippocampus. Animal studies demonstrate restored spatial learning in aged rats, making it a compelling candidate for combating memory loss associated with aging.
Neuroplasticity Enhancement
Unlike nootropics that work through neurotransmitter modulation, dihexa drives physical neuroplasticity — the formation of new dendritic spines and synapses. This makes it ideal for individuals looking to enhance their brain's capacity for learning and adaptation at a structural level.
Neurodegenerative Disease Research
Preclinical evidence in APP/PS1 Alzheimer's mice and scopolamine-induced amnesia models positions dihexa as a leading research compound for neurodegenerative disease. It is patented for potential use in Alzheimer's and Parkinson's diseases, with ongoing interest from the research community.
Advanced Nootropic Stacking
Dihexa's unique mechanism (HGF/c-Met potentiation) is complementary to most other nootropic mechanisms, making it an excellent addition to advanced cognitive enhancement protocols when combined with choline donors, racetams, or adaptogens.
P21 (P021)
Neurogenesis and Brain Cell Renewal
P21 was specifically designed to promote adult hippocampal neurogenesis — the birth of new neurons in the brain's primary memory center. Preclinical studies demonstrate robust increases in neuronal progenitor cell proliferation and maturation of newborn neurons into functional, synaptically connected cells in the dentate gyrus.
Alzheimer's Disease Research
P21 shows remarkable disease-modifying potential in 3xTg-AD Alzheimer's mice: reducing tau hyperphosphorylation, lowering soluble Aβ levels, rescuing synaptic deficits, and restoring cognitive function over 12-month treatment periods. Its mechanism targets the underlying pathology rather than just symptoms.
BDNF Enhancement
For individuals seeking to boost brain-derived neurotrophic factor levels, P21 provides a targeted approach through its inhibition of LIF signaling, leading to sustained BDNF upregulation. BDNF is critical for synaptic plasticity, memory formation, and neuronal survival.
Long-Term Neuroprotection
With demonstrated safety in animal studies up to 12 months of continuous treatment and without the adverse effects of native CNTF, P21 is suited for extended neuroprotective protocols aimed at maintaining cognitive function during aging.
Safety Profile
Side
effects
Dihexa
Common
- Headache
- Vivid dreams or altered sleep patterns
- Emotional sensitivity
- Mild fatigue during adjustment
Uncommon
- Gastrointestinal discomfort
Serious
- Theoretical oncogenic risk from c-Met activation
P21 (P021)
Common
- Nasal irritation (intranasal route)
- Mild headache
- Mild fatigue during adjustment
Uncommon
- Vivid dreams
- Mood fluctuations
Serious
- No serious adverse effects observed in preclinical studies
Research Status
Safety
& evidence
Dihexa
Evidence Level
Preclinical only — animal and cell-culture studies; no human trials
FDA Status
Research compound
Safety Overview
Dihexa has demonstrated a favorable safety profile in published animal studies, with no reported tumorigenic effects or organ toxicity at cognitive-enhancing doses. However, the compound has not undergone formal human clinical trials, and long-term safety data does not exist. The primary theoretical safety concern is sustained activation of the HGF/c-Met proto-oncogenic pathway, which could theoretically promote tumor initiation or growth. The extremely long half-life (~12 days) raises additional concerns about compound accumulation with chronic daily dosing. Anecdotal reports from the nootropics community generally describe good tolerability at doses of 5-20 mg daily, with headaches and vivid dreams as the most commonly reported effects.
Contraindications
- xKnown or suspected malignancy — c-Met/HGF pathway activation may promote tumor growth
- xPregnancy and breastfeeding — no safety data available
- xHistory of cancer, particularly HGF/c-Met-driven tumors (hepatocellular, gastric, lung)
- xSevere hepatic impairment
P21 (P021)
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
P21 has demonstrated an excellent safety profile in preclinical animal studies, with up to 12 months of continuous treatment in mice showing no adverse effects. Critically, it does not produce the anorexia, hyperalgesia, and weight loss that limited clinical development of the parent molecule CNTF. The compound was specifically engineered to retain CNTF's neurotrophic benefits while eliminating its systemic side effects. No organ toxicity, tumorigenic effects, or behavioral abnormalities were reported in any published study.
Contraindications
- xKnown hypersensitivity to any component of the peptide formulation
- xPregnancy and breastfeeding — no reproductive safety data available
- xActive brain tumors or history of CNS malignancies — neurogenesis-promoting compounds may theoretically affect tumor growth
- xChildren and adolescents — effects on developing brains not studied
Decision Guide
Which is
right for you?
Choose Dihexa if...
- Cognitive enhancement and memory consolidation in age-related decline
- Supporting neuroplasticity and new synaptic connection formation
- Research into neurodegenerative disease therapeutics (Alzheimer's, Parkinson's)
- Nootropic stacking for individuals seeking enhanced learning capacity
Choose P21 (P021) if...
- Supporting neurogenesis and brain cell renewal in age-related cognitive decline
- Enhancing learning capacity and memory consolidation
- Neuroprotection through BDNF upregulation and tau pathology reduction
- Research into disease-modifying Alzheimer's disease therapies